Kinetics of peg-filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplantation

Piccirillo, Nicola; Matteis, Silvia De; Vita, Serena De; Laurenti, Luca; Chiusolo, Patrizia; Sorà, Federica; Reddiconto, Giovanni; D’Onofrio, Giuseppe; Leone, Giuseppe; Sica, Simona

doi:10.1038/sj.bmt.1705772

Search citation statements

Order By: Relevance

Paper Sections

Select...

Pegfilgrastim To Accelerate Granulocyte Recovery After Autol1

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2009

2019

Publication Types

Select...

Article3

Book1

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…46 This complication has already been reported in patients and healthy donors after the administration of conventional G-CSF, and appears to be a general risk associated with the administration of myelopoietic growth factors. 47 Similar data on pegfilgrastim serum levels and time to haematopoietic reconstitution was later reported by Piccirillo et al 48 in 18 patients with various haematological malignancies. Review of pegfilgrastim for SC mobilization G Kobbe et al…”

Section: Pegfilgrastim To Accelerate Granulocyte Recovery After Autolsupporting

confidence: 68%

Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT

Kobbe

Bruns

Fenk

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Pegfilgrastim To Accelerate Granulocyte Recovery After Autolsupporting

confidence: 68%

Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT

Kobbe

Bruns

Fenk

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Finally, the addition of Peg-filgrastim at the end of chemotherapy might enhance GO-induced apoptosis and inhibit P-gp expression in AML cells 18,19…”

Section: Discussionmentioning

confidence: 99%

Ara-C, Idarubicine and Gentuzumab Ozogamicin (Aim) as Salvage Treatment in Advanced Acute Myeloid Leukemia Patients

Capria

Trisolini

Minotti

et al. 2012

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Long-term survival of relapsed/refractory acute myeloid leukemia (AML) remains a major problem, particularly in patients not eligible for transplantation.We hereby evaluated the feasibility and efficacy of adding Gemtuzumab Ozogamicin to salvage chemotherapy (Ara-C, Idarubicine, Peg-Filgrastim) in relapsed/refractory AML. The main endpoints were: the rate of complete remissions (CR) and the proportion of patients capable of undergoing a stem cell transplant.Fourty-two patients were enrolled. The overall CR rate was 76% and no induction deaths were reported. In 56% of patients, a transplant procedure could be performed. The treatment schedule proved feasible and well tolerated, providing a high CR rate and a useful bridge to transplant.

show abstract